Official record
- Identifier
NCT05965999- Recruiting locations
country
United States- Interventions studied
- EsoCheck®EsoGuard®
- Lead sponsor
- Lucid Diagnostics, Inc.
- Target enrolment
- 8000 participants
- Study type
- OBSERVATIONAL
- Phase
- Not provided in the official record
- Status
- Recruiting
- First posted
- Jul 28, 2023
- Last updated on the registry
- Sep 28, 2026
- Age
- Not provided in the official record
- Sex
- ALL
- Study contact
- The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.
- Eligibility criteria
Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.
Inclusion Criteria: 1. Individuals in whom a healthcare provider has made the independent clinical decision to screen for BE/EAC (based on assessment of elevated disease risk) using EsoGuard for analysis of cell samples collected with EsoCheck 2. Provided written informed consent for prospective registry participation/data collection Exclusion Criteria: 1. Inability to provide written informed consent 2. Subjects who fall outside the eligible population defined by the EsoCheck device Instructions For Use (IFU)
- Indexed under
- Esophageal Cancer